Moody Aldrich Partners LLC lifted its position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) by 17.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 93,668 shares of the biopharmaceutical company’s stock after acquiring an additional 13,826 shares during the period. Moody Aldrich Partners LLC’s holdings in Dicerna Pharmaceuticals were worth $2,379,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its position in Dicerna Pharmaceuticals by 14.1% in the 1st quarter. BlackRock Inc. now owns 5,058,547 shares of the biopharmaceutical company’s stock valued at $92,926,000 after acquiring an additional 625,457 shares during the period. Wellington Management Group LLP lifted its position in shares of Dicerna Pharmaceuticals by 1,345.0% during the first quarter. Wellington Management Group LLP now owns 3,870,016 shares of the biopharmaceutical company’s stock valued at $71,092,000 after purchasing an additional 3,602,192 shares in the last quarter. State Street Corp lifted its position in shares of Dicerna Pharmaceuticals by 1.5% during the first quarter. State Street Corp now owns 1,683,085 shares of the biopharmaceutical company’s stock valued at $30,918,000 after purchasing an additional 24,815 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its position in shares of Dicerna Pharmaceuticals by 52.7% during the second quarter. Candriam Luxembourg S.C.A. now owns 1,343,269 shares of the biopharmaceutical company’s stock valued at $34,121,000 after purchasing an additional 463,769 shares in the last quarter. Finally, Driehaus Capital Management LLC increased its holdings in Dicerna Pharmaceuticals by 2.3% during the first quarter. Driehaus Capital Management LLC now owns 1,014,548 shares of the biopharmaceutical company’s stock worth $18,637,000 after buying an additional 22,628 shares during the last quarter. 82.77% of the stock is owned by institutional investors.
In related news, COO James B. Weissman sold 4,360 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $20.20, for a total transaction of $88,072.00. Following the completion of the sale, the chief operating officer now directly owns 26,220 shares in the company, valued at $529,644. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bob D. Brown sold 8,185 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $26.50, for a total value of $216,902.50. Following the sale, the insider now owns 13,185 shares of the company’s stock, valued at $349,402.50. The disclosure for this sale can be found here. Insiders sold 60,586 shares of company stock valued at $1,416,813 over the last three months. 11.30% of the stock is currently owned by corporate insiders.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.59). Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. The company had revenue of $34.03 million during the quarter, compared to analysts’ expectations of $59.61 million. Equities analysts forecast that Dicerna Pharmaceuticals Inc will post 0.18 EPS for the current fiscal year.
DRNA has been the subject of several recent research reports. SunTrust Banks lifted their target price on shares of Dicerna Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Royal Bank of Canada started coverage on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 12th. They set an “outperform” rating and a $35.00 target price for the company. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. SVB Leerink boosted their price objective on shares of Dicerna Pharmaceuticals from $35.00 to $38.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, B. Riley restated a “buy” rating and issued a $30.00 price objective on shares of Dicerna Pharmaceuticals in a report on Monday, June 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $33.27.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Read More: What is a dividend reinvestment plan?
Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA).
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.